Montreal, Canada
Endocision, founded in 2019, is a Canadian startup operating at the intersection of Biotechnology, Health Care, Manufacturing, and Medical Devices. The company is on a mission to advance lung disease care through its slogan: "Developing innovative minimally-invasive solutions for lung disease diagnosis and treatment."
Key to Endocision's value proposition is its development of novel devices that offer minimally-invasive options for lung disease diagnosis and treatment. These devices are particularly significant because they are compatible with both bronchoscopy and robotic bronchoscopy technologies, adding versatility to their application in medical procedures.
The company has achieved an essential milestone by being certified to ISO 13485:2016 MDSAP, highlighting its commitment to meeting global quality standards in medical device manufacturing. While the company lacks recent investment activity, its innovative approach positions it for potential interest from forward-looking investors focused on revolutionizing healthcare solutions.
